Document is current
Any future updates will be listed below
-
Authors
Jerzak, Katarzyna J.
Razis, Evangelia D.
Agostinetto, Elisa
Brastianos, Priscilla K.
Gatti-Mays, Margaret E.
Ahluwalia, Manmeet S.
Anders, Carey
Bartsch, Rupert
Cardoso, Fatima
de Vries, Elisabeth G. E.
El-Abed, Sarra
Linderholm, Barbro
O’Sullivan, Ciara C.
Sahgal, Arjun
Sammons, Sarah
Spears, Patricia A.
Schumacher-Wulf, Eva
Palmieri, Carlo
Lin, Nancy U.
,
- License Information
-
More Information
Article History
Received: 10 April 2025
Accepted: 27 October 2025
First Online: 20 December 2025
Competing interests
: K.J.J. reports speaker/advisor board/consultant for: Amgen, AstraZeneca, Apo-biologix, Daiichi Sankyo, Eli Lilly, Esai, Genomic Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics Inc, Pfizer, Roche, Novartis, Organon and research funding from: Astra Zeneca, Eli Lilly, Pfizer. EDR reports Honoraria Astra Zeneca Servier Novartis, Conference Attendance support Gilead, Astra Zeneca, Integris, Servier, MSD, BMS, Pfizer, Genesis Pharma. AG reports Honoraria: Eli Lilly, AstraZeneca, Advisory Board: AstraZeneca Research grant to my Institution from Gilead, Support for attending medical conferences from: Novartis, Roche, Eli Lilly, Genetic, Instituto Gentili, Daiichi Sankyo, AstraZeneca. CA has received research funding PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, Astra Zeneca, Elucida, Caris, Incyclix, Beigene; she reports compensated consulting from: Genentech, Eisai, IPSEN, Seattle Genetics, Astra Zeneca, Novartis, Immunomedics, Elucida, Athenex, Roche; as well as Royalties from: UpToDate, Jones and Bartlett. PKB has consulted for ElevateBio, Genentech, Angiochem, Tesaro, Axiom Healthcare Strategies, InCephalo Therapeutics, Medscape, MPM Capital Advisors, Dantari, SK Life Sciences, Pfizer, CraniUS, Kazia, Sintetica, Voyager Therapeutics, Advise Connect Inspire and Atavistik, and has received research support (institution) from Merck, Mirati, Eli Lilly and Kinnate. NUL reports Institutional Research Support: Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca, Consulting Honoraria: Seattle Genetics, Daiichi-Sankyo, AstraZeneca, Olema Pharmaceuticals, Janssen, Blueprint Medicines, Stemline/Menarini, Artera Inc., Eisai, Travel: Olema Pharmaceuticals, AstraZeneca. BL reports speaker/advisory board for Astra Zeneca, Daiichi-Sankyo, Pfizer, Gilead, Eli Lilly, Stemline/Menarini and Novartis. FC reports consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Bayer, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime. E.G.E.de Vries reports Institutional Financial Support for her advisory role from Crescendo Biologics, Daiichi Sankyo and NSABP, and Institutional Financial Support for clinical trials or contracted research from Amgen, Genentech, Roche, Bayer, Servier, Regeneron and Crescendo Biologics, all outside the submitted work. CP reports consulting or advisory roles for, Daiichi Sankyo, Exact Sciences, Gilead, MSD, Menarini/Stemline Novartis, Pfizer and Seagen; research funding from, Pfizer, Daiichi Sankyo, Exact Sciences, Gilead and Seagen and travel support from, AZ, Gilead, Novartis, Pfizer and Roche. COS reports speaker/advisor board/consultant for: Pfizer, Astra Zeneca; Institutional Research Support: Pfizer, Sermonix and Bavarian Nordic.
